SUVRETTA CAPITAL MANAGEMENT, LLC
Long book
$3.69B
Q1 2026
Positions
88
Top-10 weight
42%
concentration
Last quarter
+27.5%
SPY +14.8%
Turnover
30%
of book per quarter
Strategy in plain words
auto-generated from filingsSUVRETTA CAPITAL MANAGEMENT, LLC is a diversified fundamental manager, specialised in healthcare (67% of the long book), running a $3.69B US long book across 88 positions.
The portfolio is moderately concentrated (top 10 ≈ 42% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: ARCUTIS BIOTHERAPEUTICS INC, VERADERMICS INC, PALVELLA THERAPEUTICS INC, APELLIS PHARMACEUTICALS INC, LEGEND BIOTECH CORP-ADR.
Over the last 9 quarters its long book ran on average 1.5pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-2.6%
Q2 2024
+10.6%
Q3 2024
-4.1%
Q4 2024
-10.3%
Q1 2025
+9.2%
Q2 2025
+18.9%
Q3 2025
+9.7%
Q4 2025
-5.1%
Q1 2026
+27.5%
Sector allocation
Healthcare 62%
Consumer discretionary 10%
Technology 8%
Other 8%
Financials 6%
Services media 3%
Industrials 3%
Materials 1%
Long book by quarter
What does SUVRETTA CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 12.3M | $290.4M | 7.9% | +3.0% |
| MANE VERADERMICS INC | Healthcare | 4.2M | $263.3M | 7.1% | New |
| PVLA PALVELLA THERAPEUTICS INC | Healthcare | 1.2M | $143.8M | 3.9% | +29.3% |
| APLSUSD APELLIS PHARMACEUTICALS INC | — | 3.5M | $141.5M | 3.8% | -15.0% |
| BNTC BENITEC BIOPHARMA INC | Healthcare | 11.5M | $123.0M | 3.3% | Held |
| CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 3.8M | $116.1M | 3.1% | +113.9% |
| IMTX IMMATICS NV | Healthcare | 11.2M | $110.1M | 3.0% | Held |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 5.0M | $108.7M | 2.9% | -3.0% |
| EYPT EYEPOINT INC | Healthcare | 8.3M | $106.9M | 2.9% | +6.0% |
| AVBP ARRIVENT BIOPHARMA INC | Healthcare | 4.4M | $101.5M | 2.8% | +7.2% |
| NVDA NVIDIA CORP | Technology | 574.7K | $100.2M | 2.7% | +8.2% |
| META META PLATFORMS INC-CLASS A | Technology | 169.7K | $97.1M | 2.6% | +0.4% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 4.8M | $96.0M | 2.6% | Held |
| GE GENERAL ELECTRIC | Industrials | 310.3K | $88.0M | 2.4% | Held |
| BHVN BIOHAVEN LTD | Healthcare | 10.3M | $87.0M | 2.4% | Held |
| SYY SYSCO CORP | Consumer discretionary | 1.2M | $82.7M | 2.2% | +7.0% |
| MGM MGM RESORTS INTERNATIONAL | Services media | 2.2M | $79.9M | 2.2% | +79.6% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 14.3M | $75.7M | 2.1% | +0.9% |
| HD HOME DEPOT INC | Consumer discretionary | 221.6K | $72.9M | 2.0% | -8.0% |
| KURA KURA ONCOLOGY INC | Healthcare | 8.6M | $69.7M | 1.9% | Held |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 4.2M | $69.5M | 1.9% | +25.8% |
| BAC BANK OF AMERICA CORP | Financials | 1.3M | $63.1M | 1.7% | -14.7% |
| ERAS ERASCA INC | Healthcare | 3.4M | $55.6M | 1.5% | -76.3% |
| COF CAPITAL ONE FINANCIAL CORP | Financials | 302.4K | $55.2M | 1.5% | +75.8% |
| ZURA ZURA BIO LTD | Healthcare | 9.1M | $53.9M | 1.5% | +62.9% |
| AMZN AMAZON.COM INC | Consumer discretionary | 254.0K | $52.9M | 1.4% | -37.5% |
| AMD ADVANCED MICRO DEVICES | Technology | 257.2K | $52.3M | 1.4% | -34.0% |
| FULC FULCRUM THERAPEUTICS INC | Healthcare | 6.6M | $50.3M | 1.4% | Held |
| VMC VULCAN MATERIALS CO | Materials | 181.6K | $49.4M | 1.3% | New |
| FERG FERGUSON ENTERPRISES INC | Consumer discretionary | 211.9K | $49.4M | 1.3% | +33.1% |
| APO APOLLO GLOBAL MANAGEMENT INC | Financials | 387.7K | $43.2M | 1.2% | -28.6% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.5M | $41.7M | 1.1% | Held |
| CRNX CRINETICS PHARMACEUTICALS IN | Healthcare | 1.0M | $37.9M | 1.0% | New |
| CTNM CONTINEUM THERAPEUTICS INC-A | Healthcare | 2.8M | $37.1M | 1.0% | Held |
| USFD US FOODS HOLDING CORP | Consumer discretionary | 396.0K | $36.5M | 1.0% | New |
| PFGC PERFORMANCE FOOD GROUP CO | Consumer discretionary | 386.9K | $33.1M | 0.9% | New |
| REPL REPLIMUNE GROUP INC | Healthcare | 4.2M | $32.3M | 0.9% | +11615.0% |
| AURA AURA BIOSCIENCES INC | Healthcare | 4.4M | $29.3M | 0.8% | Held |
| UNH UNITEDHEALTH GROUP INC | Financials | 100.6K | $27.2M | 0.7% | -9.6% |
| PROK PROKIDNEY CORP | Healthcare | 12.3M | $22.1M | 0.6% | Held |
| LTH LIFE TIME GROUP HOLDINGS INC | Services media | 510.3K | $13.7M | 0.4% | New |
| WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 3.7M | $12.8M | 0.3% | Held |
| ABEO ABEONA THERAPEUTICS INC | Healthcare | 2.7M | $12.0M | 0.3% | Held |
| WING WINGSTOP INC | Consumer discretionary | 59.5K | $9.2M | 0.3% | New |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 123.9K | $7.8M | 0.2% | -64.9% |
| LXEO LEXEO THERAPEUTICS INC | Healthcare | 1.3M | $7.2M | 0.2% | Held |
| COHR COHERENT CORP | Other | 30.0K | $7.1M | 0.2% | -78.2% |
| IFRX INFLARX NV | Healthcare | 7.9M | $7.1M | 0.2% | Held |
| DHR DANAHER CORP | Technology | 36.4K | $6.9M | 0.2% | -85.1% |
| ABT ABBOTT LABORATORIES | Healthcare | 66.9K | $6.9M | 0.2% | +31.2% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 89 | $3.92B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 93 | $4.88B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 93 | $3.91B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 98 | $3.32B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 100 | $2.69B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 96 | $2.93B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 98 | $3.13B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 98 | $2.72B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 101 | $2.69B | canonical | SEC ↗ |